Organization (Industry)
Meiji Seika Pharma Co., Ltd. (Japan)
ClinicalTrials.gov lists Meiji Seika Pharma Co., Ltd. (Japan) as lead sponsor of 10 trials. It has 3 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Meiji, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Meiji Seika Pharma Co., Ltd. (Japan): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Onychomycosis | 2 |
| Anxiety Disorders | 1 |
| Bronchiolitis | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Graft vs Host Disease | 1 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 3 |
| 2021 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 5 |
| 2010 | 1 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| ME1111 Solution, High strength | Onychomycosis | Phase 2 | 1 |
| Matching Vehicle Solution | Onychomycosis | Phase 2 | 1 |
| ME1111 Solution, Low strength | Onychomycosis | Phase 2 | 1 |
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ADALIMUMAB | 1 |
| TRASTUZUMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 0 of 2 on time (n=2) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Antimicrobial agents and chemotherapy | 1 |
| BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 1 |
| Neuropsychopharmacology reports | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 537 | 9 | 2025-09-23 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 6 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 6 | 2013-12-20 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Meiji Seika Pharma Co., Ltd. | Motosu-gun, JP | FDA, Health Canada | |
| Meiji Seika Pharma Co., Ltd. | Kitakami, JP | FDA | |
| Meiji Seika Pharma Co. Ltd. | Kitakami-shi, JP | Health Canada |
Latest dated events (564)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-12-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-03-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-02-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-10-08 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 564 events.
Biomarker capability evidence (22)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BTBD8 | Trial sponsor | Named in trial inclusion criteria |
| HLA-DMB | Trial collaborator | Primary endpoint in a Phase 3 trial |
| PRL | Trial collaborator | Primary endpoint in a Phase 3 trial |
| CSF2 | Trial collaborator | Named in trial exclusion criteria |
| CSF3 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 22 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.